Target intelligence / Profile preview

Dedicator of cytokinesis protein 10 (DOCK10)

Target
DOCK10
Molecular classification
Guanine nucleotide exchange factor (GEF), RhoGEF, Enzyme, Cytoplasmic signaling protein, DOCK-D (Zizimin) subfamily
01

Overview

Dedicator of cytokinesis protein 10 (DOCK10) is a large (~240 kDa) cytoplasmic signaling protein and member of the DOCK-D subfamily of guanine nucleotide exchange factors (GEFs), characterized by DOCK homology domains (DHR1 and DHR2), and an N-terminal pleckstrin homology (PH) domain[1][3][8]. DOCK10 functions as a dual-specificity GEF, directly activating the small Rho GTPases Rac1 and Cdc42 by facilitating the exchange of GDP for GTP, a key event in intracellular signal transduction[2][3]. It is essential for dendritic spine morphogenesis in neurons and plays a role in B-cell activation, proliferation, and lymphopoiesis[2][3]. DOCK10 is expressed in a range of tissues including immune cells, brain, spleen, lung, and thymus, and is upregulated in activated B-lymphocytes and some carcinomas[1][4]. Elevated expression has been implicated in chronic lymphocytic leukemia and aggressive papillary thyroid carcinoma, and germline variation is linked to neurodevelopmental disorders[1][3][7]. No direct pharmacological inhibitors or approved interacting drugs are currently described for DOCK10.

Other names
Dedicator of cytokinesis 10Zizimin-3Zizimin3DRIP2KIAA0694Nbla10300dopamine receptor interacting protein 2ZIZ3
02

Mechanism of action

Guanine nucleotide exchange for Cdc42 and Rac1 (conversion of inactive GDP-bound GTPases to active GTP-bound form)

03

Biological functions

Activation of Rho GTPases (Rac1, Cdc42)Signal transductionDendritic spine morphogenesisB-cell activation and proliferationB-cell lymphopoiesisRegulation of Fc epsilon receptor II (FCER2/CD23) expressionNeuronal development
04

Disease associations

Cancer (notably aggressive papillary thyroid carcinoma)Immunodeficiency/immune dysregulationNeurodevelopmental disorders (e.g., autism spectrum disorder, developmental delay)Other possible rare disorders (case reports)
05

Safety considerations

Poorly characterized as a therapeutic targetPotential for immunomodulation and neurodevelopmental effects if targeted due to roles in immune cells and the brainGermline pathogenic variants may be associated with developmental syndromes
06

Biomarkers

Overexpression in chronic lymphocytic leukemia (CLL) B cells and aggressive thyroid carcinomasUpregulation in activated B cells

Beyond the preview

Go deeper on Dedicator of cytokinesis protein 10 (DOCK10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicator of cytokinesis protein 10 (DOCK10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call